Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

Scientists have uncovered a way to promote weight loss and improve blood sugar control without the unpleasant side effects of ...

Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

A recent survey revealed that over 1 in 10 Americans have used a GLP-1 drug for weight loss.Survey results indicated that up ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results ...

Ali Eastburn was looking forward to her son's wedding when her side-effects from weight loss drugs went from bad to worse ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

Key Takeaways More than 1 in 10 Americans has tried a GLP-1 drug50- to 64-year-olds report the most useSide effects like ...